The prognosis of refractory/relapsed acute myeloid leukemia (AML) remains poor. The
complete response (CR) rate after relapse is around 25%, with 11% of patients still alive …

Cytarabine combined with an anthracycline or an anthracenedione represents the usual
intensive induction therapy for the treatment of AML. However, this protocol induces severe …

目的: 评价MAC 方案作为老年急性髓系白血病(AML) 患者(≥ 55 岁) 挽救性治疗方案的疗效及
安全性. 方法: 收集33 例应用MAC 方案进行挽救性治疗的复发或诱导治疗未缓解的老年AML …

Current salvage therapies for relapsed acute myeloid leukemia (AML) are unsatisfactory. We
retrospectively evaluated the efficacy and toxicity of fractionated doses of gemtuzumab …

The treatment of acute myeloid leukaemia has remained largely unchanged for the last 30
years since the advent of combination chemotherapy with cytarabine arabinoside and …

Objective Little data exist regarding long‐term survival in elderly patients with acute myeloid
leukemia (AML). Methods In view of the fact that most deaths occurred during the first 3 yr …

New therapeutic strategies for high-risk acute myeloid leuke... : Current Opinion in
Hematology New therapeutic strategies for high-risk acute myeloid leukemia : Current …

Targeted therapy of acute myeloid leukemia (AML) with monoclonal antibodies (MoAbs) has
thus far been mostly directed at CD33, CD45, and CD66. The notion that some AMLs may …

Przeciwciała monoklonalne (mAb) podawane w monoterapii lub terapii skojarzonej
stanowią skuteczną opcję terapeutyczną w przypadku nowotworów hematologicznych …

Les leucémies aiguës myéloïdes (LAM) de l'adulte jeune représentent des entités
hétérogènes avec un pronostic contrasté. La classification pronostique de l'European …